This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.
In the first trial, at the Peter MacCallum Cancer Center in Australia, CRC patients receiving just divarasib had a 35.9% positive response rate, which was considered extremely promising.
After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.
Sustainable aviation fuel just crossed the Atlantic on its own, with no fossil jet fuel in the tank. A Gulfstream G600 flew from Savannah, Georgia to Farnborough, England in under seven hours, becoming the first aircraft to make the transatlantic journey on 100% SAF. The engines weren’t modified for the trip, hinting that existing planes could one day run on cleaner fuel without expensive retrofits. Gulfstream now plans to share the flight data with U.S. regulators to help certify full SAF use beyond today’s blended limits. For an industry where battery and hydrogen flight remain distant, this single crossing offers something rare: a glimpse of long-haul aviation that could actually clean up before 2050.
Prison education just crossed a remarkable threshold: sixteen men at Stateville Correctional Center in Illinois became the first incarcerated students in the U.S. to earn bachelor’s degrees from a top-ten ranked university. Northwestern’s program now enrolls around 100 students across two facilities, including a women’s prison, with graduates already planning law school and youth-focused nonprofits. One graduate’s mother, who hadn’t seen her son in nearly two decades, watched him walk across the stage in cap and gown. With Pell Grants finally restored to incarcerated students after a nearly thirty-year ban, this ceremony hints at what’s possible when elite institutions treat people behind bars as full participants in higher learning — a shift that could ripple through prisons and universities alike.
Whole-eye transplant surgery has been performed successfully for the first time, with a team at NYU Langone Health spending more than 20 hours combining a donor eyeball, a partial face transplant, and a stem cell infusion into the optic nerve. The patient, Aaron James, lost much of his face in a 2021 electrical accident, and surgeons had carefully preserved his optic nerve in anticipation of exactly this kind of operation. Doctors say the transplanted eye is healthy and blood is flowing to the retina, though James has not regained sight. Restoring vision may still be years away, but this opens a real door for people with catastrophic eye injuries — proof that something once considered impossible is now a starting point.
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
Gene therapy has restored partial hearing in four out of five deaf children in a Shanghai trial, with each child regaining roughly 60 to 65 percent of typical hearing ability. The Fudan University team used a harmless virus to ferry a working copy of the otoferlin gene directly into the inner ear, where it began producing the protein these children had been missing since birth. Most had heard little or nothing their whole lives, so even partial hearing opens a window for spoken language to develop during early childhood. Parallel trials at Cambridge and Regeneron suggest the field is converging on a shared approach — a hopeful proof of concept that could one day extend to many more forms of inherited deafness.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
The researchers from the University of Cambridge found that, on its own, the blood test could diagnose up to 30% of patients with BD, but combining it with the online psychiatric assessment significantly improved the diagnosis rate, especially in people whose diagnosis was not obvious.
Cervical cancer survival rates could improve dramatically after a major clinical trial found that adding a short course of chemotherapy before standard treatment reduces the risk of death or recurrence by 35%. Led by University College London researchers and funded by Cancer Research U.K., the trial showed 80% of women using the new approach were alive at five years, compared to 72% receiving standard treatment alone. The finding is considered the biggest advance in cervical cancer outcomes in over 20 years. Crucially, the drugs involved are already approved, widely available, and inexpensive, meaning the protocol could be adopted globally without new approvals or manufacturing delays.
